) unveiled the pricing of $2 billion senior notes in the form of
bond issuance, which will be comprised four groups of $500
million each (aggregate principal amount).
The $500 million aggregate principal amount of 1.35% senior notes
will mature in 2016 whereas the $500 million aggregate principal
amount of 2.55% senior notes is expected to mature in 2019. The
other two groups of $500 million carry interest rates of 4.20%
and $5.40 % due in 2023 and 2043, respectively. The offering is
anticipated to close on Nov 29, 2013.
The net proceeds will be used primarily to fund its impending
acquisition of Agila Specialties - the injectable drugs division
of India's Strides Arcolab. Through this deal, expected to close
by year end, Mylan intends to strengthen its presence in the high
potential generic injectables market. Mylan also intends to
utilize the funds for general corporate purposes and share
Apart from the pricing of senior notes, Mylan was also in the
news when it launched its generic version of
) attention deficit hyperactivity disorder (ADHD) treatment,
Focalin XR (dexmethylphenidate hydrochloride extended-release)
capsules (30 mg) in the U.S. With Mylan being the first to file,
the company will enjoy 180 days of marketing exclusivity. As per
IMS data, as of Sep 30, 2013, Focalin annual sales were
approximately $67.34 million in the U.S.
Mylan, one of the largest players in the global generics market,
has a presence in approximately 140 countries. As of Nov 18,
2013, the company had 179 abbreviated new drug applications
pending approval by the U.S. Food and Drug Administration (FDA),
representing $90.5 billion in annual sales. These include 40
first-to-file opportunities, representing $24.1 billion in annual
sales. The data released by IMS Health is for the twelve-month
period ending Jun 30, 2013.
Mylan's generic unit is its main growth driver. Bulk of the
revenues of the company is generated from generic third-party net
sales, derived from sales in North America, Europe, the Middle
East & Africa and Asia-Pacific. Moreover, Mylan has a strong
generic pipeline and should continue benefiting from a large
number of high-value branded drugs scheduled to go off patent in
the next couple of years. These patent expirations should boost
the generic product portfolio of Mylan.
Mylan carries a Zacks Rank #3 (Hold).
), another generic player, looks more attractive with a Zacks
Rank #2 (Buy).
), a leading player in the ADHD market, carries a Zacks Rank #1
ACTAVIS PLC (ACT): Free Stock Analysis Report
MYLAN INC (MYL): Free Stock Analysis Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis
SHIRE PLC-ADR (SHPG): Free Stock Analysis
To read this article on Zacks.com click here.